Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | ORKA | - | - |
Stockmoo Score
1.3
|
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 44.00 (Leerink Partners, 76.78%) | Buy |
| 44.00 (Leerink Swann, 76.78%) | Buy | |
| Median | 42.50 (70.75%) | |
| Low | 40.00 (Jefferies, 60.71%) | Buy |
| Average | 42.25 (69.75%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 25.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 17 Sep 2024 | 44.00 (76.78%) | Buy | 26.47 |
| Leerink Swann | 17 Sep 2024 | 44.00 (76.78%) | Buy | 26.47 |
| LifeSci Capital | 16 Sep 2024 | 41.00 (64.72%) | Buy | 25.90 |
| Jefferies | 13 Sep 2024 | 40.00 (60.71%) | Buy | 24.89 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FAIRMOUNT FUNDS MANAGEMENT LLC | 29.62 | - | 275,000 | 8,145,500 |
| Aggregate Net Quantity | 275,000 | |||
| Aggregate Net Value ($) | 8,145,500 | |||
| Aggregate Avg. Buy ($) | 29.62 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FAIRMOUNT FUNDS MANAGEMENT LLC | Director | 11 Sep 2024 | Acquired (+) | 275,000 | 29.62 | 8,145,500 |
| TTM Dividend Yield | 6.48% |
| Expected Next Dividend Payment | Aug 2025 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 29 Aug 2024 | - | 28 Aug 2024 | 1.613 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2024 | 1.61 | 1 | 6.48 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |